These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

411 related items for PubMed ID: 28419995

  • 1. Hemolytic Uremic Syndrome and Kidney Transplantation: A Case Series and Review of the Literature.
    Milan Manani S, Virzì GM, Giuliani A, Clementi A, Brocca A, Dissegna D, Martino F, d''Amore ESG, Ronco C.
    Nephron; 2017; 136(3):245-253. PubMed ID: 28419995
    [Abstract] [Full Text] [Related]

  • 2. Two patients with history of STEC-HUS, posttransplant recurrence and complement gene mutations.
    Alberti M, Valoti E, Piras R, Bresin E, Galbusera M, Tripodo C, Thaiss F, Remuzzi G, Noris M.
    Am J Transplant; 2013 Aug; 13(8):2201-6. PubMed ID: 23731345
    [Abstract] [Full Text] [Related]

  • 3. Hemolytic uremic syndrome in children.
    Talarico V, Aloe M, Monzani A, Miniero R, Bona G.
    Minerva Pediatr; 2016 Dec; 68(6):441-455. PubMed ID: 27768015
    [Abstract] [Full Text] [Related]

  • 4. Living Donor Kidney Transplantation in Atypical Hemolytic Uremic Syndrome: A Case Series.
    Duineveld C, Verhave JC, Berger SP, van de Kar NCAJ, Wetzels JFM.
    Am J Kidney Dis; 2017 Dec; 70(6):770-777. PubMed ID: 28821363
    [Abstract] [Full Text] [Related]

  • 5. Use of eculizumab and plasma exchange in successful combined liver-kidney transplantation in a case of atypical HUS associated with complement factor H mutation.
    Tran H, Chaudhuri A, Concepcion W, Grimm PC.
    Pediatr Nephrol; 2014 Mar; 29(3):477-80. PubMed ID: 24221349
    [Abstract] [Full Text] [Related]

  • 6. Tailored eculizumab therapy in the management of complement factor H-mediated atypical hemolytic uremic syndrome in an adult kidney transplant recipient: a case report.
    Xie L, Nester CM, Reed AI, Zhang Y, Smith RJ, Thomas CP.
    Transplant Proc; 2012 Dec; 44(10):3037-40. PubMed ID: 23195022
    [Abstract] [Full Text] [Related]

  • 7. Atypical hemolytic uremic syndrome.
    Loirat C, Frémeaux-Bacchi V.
    Orphanet J Rare Dis; 2011 Sep 08; 6():60. PubMed ID: 21902819
    [Abstract] [Full Text] [Related]

  • 8. Efficacy of Eculizumab Therapy for Atypical Hemolytic Uremic Syndrome Recurrence and Antibody-Mediated Rejection Progress After Renal Transplantation With Preformed Donor-Specific Antibodies: Case Report.
    Yamamoto T, Watarai Y, Futamura K, Okada M, Tsujita M, Hiramitsu T, Goto N, Narumi S, Takeda A, Kobayashi T.
    Transplant Proc; 2017 Sep 08; 49(1):159-162. PubMed ID: 28104125
    [Abstract] [Full Text] [Related]

  • 9. Posttransplant recurrence of atypical hemolytic uremic syndrome.
    Valoti E, Alberti M, Noris M.
    J Nephrol; 2012 Sep 08; 25(6):911-7. PubMed ID: 22760880
    [Abstract] [Full Text] [Related]

  • 10. Hemolytic uremic syndrome: differential diagnosis with the onset of inflammatory bowel diseases.
    Bianchi L, Gaiani F, Vincenzi F, Kayali S, Di Mario F, Leandro G, De' Angelis GL, Ruberto C.
    Acta Biomed; 2018 Dec 17; 89(9-S):153-157. PubMed ID: 30561409
    [Abstract] [Full Text] [Related]

  • 11. Prophylactic eculizumab prior to kidney transplantation for atypical hemolytic uremic syndrome.
    Weitz M, Amon O, Bassler D, Koenigsrainer A, Nadalin S.
    Pediatr Nephrol; 2011 Aug 17; 26(8):1325-9. PubMed ID: 21556717
    [Abstract] [Full Text] [Related]

  • 12. Prophylactic Eculizumab Use in Kidney Transplantation: A Review of the Literature and Report of a Case with Atypical Hemolytic Uremic Syndrome.
    Kasapoğlu U, Ruhi Ç, Tuğcu M, Boynueğri B, Titiz İ, Hançer VS, Apaydın S.
    Ann Transplant; 2015 Dec 01; 20():714-9. PubMed ID: 26621268
    [Abstract] [Full Text] [Related]

  • 13. Post-transplant recurrence of atypical hemolytic uremic syndrome in a patient with thrombomodulin mutation.
    Sinibaldi S, Guzzo I, Piras R, Bresin E, Emma F, Dello Strologo L.
    Pediatr Transplant; 2013 Dec 01; 17(8):E177-81. PubMed ID: 24118826
    [Abstract] [Full Text] [Related]

  • 14. Use of Highly Individualized Complement Blockade Has Revolutionized Clinical Outcomes after Kidney Transplantation and Renal Epidemiology of Atypical Hemolytic Uremic Syndrome.
    Zuber J, Frimat M, Caillard S, Kamar N, Gatault P, Petitprez F, Couzi L, Jourde-Chiche N, Chatelet V, Gaisne R, Bertrand D, Bamoulid J, Louis M, Sberro Soussan R, Navarro D, Westeel PF, Frimat L, Colosio C, Thierry A, Rivalan J, Albano L, Arzouk N, Cornec-Le Gall E, Claisse G, Elias M, El Karoui K, Chauvet S, Coindre JP, Rerolle JP, Tricot L, Sayegh J, Garrouste C, Charasse C, Delmas Y, Massy Z, Hourmant M, Servais A, Loirat C, Fakhouri F, Pouteil-Noble C, Peraldi MN, Legendre C, Rondeau E, Le Quintrec M, Frémeaux-Bacchi V.
    J Am Soc Nephrol; 2019 Dec 01; 30(12):2449-2463. PubMed ID: 31575699
    [Abstract] [Full Text] [Related]

  • 15. Efficacy and Safety of Eculizumab in Pediatric Patients Affected by Shiga Toxin-Related Hemolytic and Uremic Syndrome: A Randomized, Placebo-Controlled Trial.
    Garnier A, Brochard K, Kwon T, Sellier-Leclerc AL, Lahoche A, Launay EA, Nobili F, Caillez M, Taque S, Harambat J, Michel-Bourdat G, Guigonis V, Fila M, Cloarec S, Djamal-Dine D, de Parscaux L, Allard L, Salomon R, Ulinski T, Frémeaux-Bacchi V, Morin C, Olivier-Abbal P, Colineaux H, Auriol F, Arnaud C, Kieffer I, Brusq C.
    J Am Soc Nephrol; 2023 Sep 01; 34(9):1561-1573. PubMed ID: 37303085
    [Abstract] [Full Text] [Related]

  • 16. [Pathophysiology of atypical hemolytic uremic syndrome. Ten years of progress, from laboratory to patient].
    Frémeaux-Bacchi V.
    Biol Aujourdhui; 2013 Sep 01; 207(4):231-40. PubMed ID: 24594571
    [Abstract] [Full Text] [Related]

  • 17. New insights into postrenal transplant hemolytic uremic syndrome.
    Zuber J, Le Quintrec M, Sberro-Soussan R, Loirat C, Frémeaux-Bacchi V, Legendre C.
    Nat Rev Nephrol; 2011 Jan 01; 7(1):23-35. PubMed ID: 21102542
    [Abstract] [Full Text] [Related]

  • 18. Use of complement monoclonal antibody eculizumab in Shiga toxin producing Escherichia coli associated hemolytic uremic syndrome: A review of current evidence.
    Mahat U, Matar RB, Rotz SJ.
    Pediatr Blood Cancer; 2019 Nov 01; 66(11):e27913. PubMed ID: 31286658
    [Abstract] [Full Text] [Related]

  • 19. Ten-year outcome of Eculizumab in kidney transplant recipients with atypical hemolytic uremic syndrome- a single center experience.
    Kant S, Bhalla A, Alasfar S, Alachkar N.
    BMC Nephrol; 2020 May 20; 21(1):189. PubMed ID: 32434487
    [Abstract] [Full Text] [Related]

  • 20. Insights from the use in clinical practice of eculizumab in adult patients with atypical hemolytic uremic syndrome affecting the native kidneys: an analysis of 19 cases.
    Fakhouri F, Delmas Y, Provot F, Barbet C, Karras A, Makdassi R, Courivaud C, Rifard K, Servais A, Allard C, Besson V, Cousin M, Châtelet V, Goujon JM, Coindre JP, Laurent G, Loirat C, Frémeaux-Bacchi V.
    Am J Kidney Dis; 2014 Jan 20; 63(1):40-8. PubMed ID: 24021908
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.